Introduction
The myb oncogene, which is unique in its hematopoietic speci®city of transformation, was ®rst discovered in two independently derived avian retroviruses (AMV and E26) which cause acute leukemia (for review see Introna et al., 1994; Gonda, 1998; Lipsick and Wang, 1999; Weston, 1999) . The normal c-myb protooncogene encodes a 75 kDa nuclear protein which is expressed at high levels and regulates proliferation and dierentiation in immature hematopoietic cells (Oh and Reddy, 1999) . Homozygous Myb mutant mice appear normal at day 13 of gestation but by day 15 are severely anemic. Embryonic erythropoiesis is not impaired, but adult-type erythropoiesis is greatly diminished (Mucenski et al., 1991) .
The c-Myb protein contains three functional domains: an amino-(N-)terminal DNA-binding domain (DBD), a centrally located acidic transcription activation domain (TA), and a carboxyl-(C-)terminal negative regulatory domain (NRD) (Aziz et al., 1995; Tomita et al., 1998) . The leucine zipper domain (Kanei-Ishii et al., 1992) and C-terminal conserved domain (Tashiro et al., 1995) are included in the NRD. Both AMV and E26 viruses encode v-Myb AMV and vMyb E26 proteins that are truncated N-and C-terminals of the cellular c-Myb protein, and the loss of these sequences is thought to be responsible for their transforming activity (Gonda and Bishop, 1983; Klempnauer et al., 1982) . We have demonstrated that the C-terminal truncated Myb protein (designated Myb ) is expressed in a human T-cell leukemia cell line, TK-6 (Tomita et al., 1998) . The Myb TK-6 caused higher transactivating activity than wild type Myb, and we suggest a role during blast transformation. Sequential deletion of c-Myb from the C-terminus results in increased DNA-binding, transcription-activating, and transforming activities (Sakura et al., 1989; Hu et al., 1991; Grasser et al., 1991) . Several phosphorylation sites have been demonstrated in the N-and C-termini of c-Myb, and some of these sites seem to be functionally important (Aziz et al., 1995; Miglarese et al., 1996) . Furthermore, the deletion of the C-terminal region including PEST sequences increased the protein stability (Bies and Wol, 1997) . These ®ndings suggest that posttranslational modi®ca-tion of the C-terminus, such as phosphorylation or degradation, plays a critical role in the regulation of cMyb function.
Meanwhile, many reports have been reported on regulation of transcription by histone acetyltransferases (HAT) (Struhl, 1998) , such as p300/CBP (Ogryzko et al., 1996; Bannister and Kouzarides, 1996) , P/CAF (Ogryzko et al., 1996) , TAFII250 (Imhof et al., 1997) , and GCN5 (Kuo et al., 1996; Wang et al., 1997) . These HATs acetylate not only histones but also certain transcription factors, such as p53 by p300 and P/CAF (Gu and Roeder, 1997; Sakaguchi et al., 1998) , TFIIF and TFIIE by p300/CBP, P/CAF, and TAFII250 (Imhof et al., 1997) , erythroid KruÈ ppel-like factor (EKLF) by p300/CBP (Zhang and Bieker, 1998) , GATA-1 by CBP (Boyes et al., 1998; Hung et al., 1999) , and Drosophila T-cell factor (dTCF) by dCBP (Waltzer and Bienz, 1998) . Increased DNA binding activity was shown by the acetylation of p53 and GATA-1. The altered transcriptional activity caused by acetylation was observed in EKLF, GATA-1, and dTCF. Taken together with a reported interaction with CBP (Dai et al., 1996) , it is not surprising that c-Myb is also an acetylated protein which is functionally regulated by acetylation.
Here we report that c-Myb is acetylated by p300 acetyltransferase at the C-terminal conserved domain in vitro and in vivo, and that c-Myb-dependent transactivating activities are modulated by acetylation. The putative acetylation sites, three lysine residues 471, 480, 485th from the translational start codon, are completely conserved among various species' c-Myb and are also conserved with other Myb family members, AMyb and B-Myb (Nomura et al., 1988; Tashiro et al., 1995) . We suggest that acetylation is a critical manner of posttranslational modi®cation of the c-Myb protein, and that the loss of these acetylation sites may explain the functional dierences between c-Myb and v-Myb.
Results

c-Myb acetylation by p300 acetyltransferase
A recent report has shown that p300/CBP coactivators, which have an intrinsic histone acetyltransferase activity (Bannister and Kouzarides, 1996; Ogryzko et al., 1996) , are capable of acetylating not only histones but also the transcription factors described above. Considering also a report that CBP binds to c-Myb (Dai et al., 1996) , resulting in enhancing Myb-dependent transactivation, we attempted to determine whether c-Myb is an acetylated protein. A series of in vitro-translated (IVT)-Myb harboring dierent deletion mutants were used as substrates ( Figure 1a ). An in vitro acetylation assay by IVT-p300 showed that the position encompassing 455 to 515 amino acids (aa), containing the`conserved domain (CS)' of c-Myb, was a domain acetylated by p300 (Figure 1b ). The quality and the quantity of the applied IVT-Myb mutants were also indicated in Figure 1b . Consistent results were obtained in three repeated experiments.
We then investigated whether c-Myb could be acetylated by p300 in vivo using anti-acetylated lysine antibody (Figure 2 ). c-Myb were transfected with or without p300 to 293T cells, and the entire cell lysate was obtained. After immunoprecipitation using antiMyb monoclonal antibody, the obtained specimen was divided equally, and used for immunoblot analysis with anti-Myb and anti-acetylated lysing antibodies. The immunoblot analysis revealed that acetylated c-Myb could be detected only in the presence of overexpressed p300, suggesting that c-Myb is an acetylated protein and that p300 is a factor acetyltransferase for c-Myb in vivo.
The acetylation sites at the carboxyl-terminal conserved region of c-Myb
The conserved region from 460 to 494 aa of human cMyb contains three lysines that are all conserved among species cloned, i.e. human, bovine, chicken, mouse, and xenopus (Figure 3a) . The three lysines are also conserved among Myb family members, A-Myb and B-Myb (Nomura et al., 1988; Tashiro et al., 1995) . We thus introduced the mutations abrogating the three conserved lysines by the substitution with alanine residues (Myb-KAmut). Analysis of the substrate suitability of wild type and mutant c-Myb fragments was then performed (Figure 3b ). The ). The whole cell lysate was subjected to immunoblot analysis (IB) with anti-p300 antibody to con®rm the overexpression of p300 (upper panel). After immunoprecipitation (IP) using anti-Myb antibody, the equally divided immunoprecipitate was subjected to immunoblot analysis using anti-Myb antibody (middle panel), and antiacetylated-lysine antibody (lower panel). Sucient c-Myb protein expression was con®rmed by using anti-Myb antibody c-Myb acetylation by p300 A Tomita et al acetylation ecacy in vivo of Myb-KAmut was approximately two-thirds of wild type c-Myb in the presence of p300, whereas immunoblot with anti-Myb antibody indicated that equivalent amounts of Myb proteins were expressed. The experiments were performed several times and consistent results were obtained.
The bromodomain of p300 is required for effective c-Myb acetylation
We next performed in vitro acetylation assays of glutathion S-transferase (GST)-fused Myb and MybKAmut proteins in the presence of N-and C-terminal truncated recombinant p300 proteins (GST-BrHAT, p300-HAT, and GST-p300-Br) and hGCN5 (GST-GCN5). Schematic representations of human p300 and its mutant derivatives, as well as hGCN5, which were fused to GST, are given in Figure 4a . Br indicates the bromodomain in which amino acid sequences are highly conserved among p300/CBP, GCN5, and P/ CAF (Dhalluin et al., 1999; Xu et al., 1998) . The quality and the quantity of puri®ed GST-Myb, -p300, and hGCN5 proteins were con®rmed by Coomassie blue staining (data not shown). The histone acetyltransferase activity of p300 mutants and hGCN5 were con®rmed by using histone as a substrate for the acetylation (Figure 4b ). This reveals that the HAT domain but not the bromodomain is indispensable for the HAT activity for histone. We subsequently performed in vitro acetylation assays for c-Myb and Myb-KAmut using these HATs (Figure 4c ). The same amounts of acetyltransferases, as indicated in Figure  4b , were applied for in this analysis. Although GSTBrHAT and p300-HAT showed almost the same HAT activity for histone (Figure 4b ), the acetylation eciency of c-Myb obtained by p300-HAT was signi®cantly lower than that obtained by GST-BrHAT ( Figure 4c , lanes 2 and 4). The acetylation band produced by GST-p300-Br alone was undetectable (lane 6). Furthermore, the acetylation activity for Myb-KAmut by GST-BrHAT was signi®cantly lower than that for c-Myb (lanes 2 and 3). Interestingly, cMyb appeared to be acetylated by hGCN5, and the acetylation level was higher than that obtained by p300 (lane 8 versus lane 2). The acetylation level of Myb-KAmut was lower than that of c-Myb (lane 9 versus lane 8). The in vitro acetylation assay was performed independently three times, and essentially the same results were obtained. These results indicate that the lysines K471/480/485 are the acetylation sites for p300, and the bromodomain of p300 in addition to the HAT domain is required for eective acetylation of c-Myb. Furthermore, hGCN5 was revealed to be an acetyltransferase for c-Myb in vitro, and the lysines K471/480/485 may also be the acetylation sites for hGCN5.
DNA binding activity of c-Myb is modulated by the acetylation with p300 in vitro We next addressed whether the acetylation of c-Myb aects its DNA binding activity. We thereby performed electrophoretic mobility shift assay (EMSA) to see the dierence of DNA binding ability to cognate Myb site (Figure 5a ). The puri®ed GST-cMyb (lanes 1 ± 6) or GST-Myb-KAmut (lanes 7 and 8) was incubated with radio-labeled oligomers containing Myb cognate site. Figure 5a (right panel). The GST-c-Myb acetylated in vitro as described in Figure  4c showed approximately ®vefold higher DNA binding anity compared to the untreated GST-cMyb (lanes 5 and 6). The untreated GST-MybKAmut (lane 7) exhibited slightly higher (1.4-fold) DNA binding activity than the untreated GST-c-Myb (lane 5). Three independent analyses were performed, and the result is depicted in Figure 5b with standard deviations. These results suggest that acetylation of cMyb by p300 in vitro increases its DNA binding activity, and that the three lysines are important for DNA binding activity of c-Myb.
c-Myb dependent transactivation activity modulated by substitution of lysine at K471/480/485 to alanine
We next examined how Myb-KAmut and wild type c-Myb aect the transactivating capacity of the two dierent promoters containing the Myb binding motif. mim-1 (Ness et al., 1989; Tomita et al., 1998) and CD34 (Melotti et al., 1994; Burn et al., 1992) promoters are reported to be transactivated by c-Myb. The triplicate trials were performed independently ®ve times, and essentially the same results were obtained. A representative data were shown in Figure 6 . The transactivating activity of the mim-1 promoter driven by Myb-KAmut was about 1.5-fold higher than that driven by c-Myb (Figure 6a ). Cotransfection of p300 enhanced the transactivation three times more than did c-Myb alone. Unexpectedly, the addition of p300 to Myb-KAmut also increased the activity. Essentially the same results were obtained when CD34 promoter was used instead (Figure 6b ).
Discussion
Phosphorylation of transcription factors is a critical posttranslational modi®cation which regulates DNA Relative DNA binding intensity is also indicated. (b) Quantitation of the c-Myb DNA binding activity from panel a. Three independent analyses were performed and the average activity measured by using BioMax software (Eastman Kodak company, New Haven, CT, USA) was shown with standard deviations c-Myb acetylation by p300 A Tomita et al binding activity, nuclear localization, protein interaction, and transactivation. Acetylation, which has been recently revealed to behave as another posttranslational modi®cation, is supposed to function in a similar manner. Actually, p300/CBP and p300/CBPassociated factor (P/CAF) both acetylate p53 in response to DNA-damage and increase the ability of p53 to bind to its cognate DNA site (Gu and Roeder, 1997; Sakaguchi et al., 1998) . The DNA binding activity of GATA-1 is also reported to be upregulated by its acetylation (Boyes et al., 1998) . In contrast, another report contradicts this (Hung et al., 1999) by the similar method to that used in the study. Recently, C-terminal acetylation of p53 has been shown to be regulated by its N-terminal phosphorylation induced by DNA damage, indicating the existence of an intimate cascade between phosphorylation and acetylation (Sakaguchi et al., 1998; Liu et al., 1999) . In the case of Myb, phosphorylation at serine 528 in the carboxyl-terminal negative regulatory domain (NRD) has been shown to occur (Aziz et al., 1995; Miglarese et al., 1996) . Interestingly, the substitution of serine 528 with alanine did not aect the DNA-binding activity, but increased transactivation to CD34 promoter (Miglarese et al., 1996) , suggesting that the phosphorylation of serine 528 aects transcriptional activity of c-Myb by regulating interactions with other proteins. The possible association between phosphorylation and acetylation of c-Myb should be clari®ed for a full understanding of the posttranslational modi®cations responsible for full transactivation of c-Myb. Referring to the case of p53 acetylation (Gu and Roeder, 1997) , we thus hypothesize that the C-terminal tail of c-Myb, presumably having a positive charge without acetylation, interacts with the N-terminal portion. This may be in line with the reports that the Cterminal domain of c-Myb could interact with another domain in sis and/or in trans (Dubendor et al., 1992; Dash et al., 1996; Vorbrueggen et al., 1994; Ness, 1999) . Upon acetylation at K471/480/485, the positive charge may be neutralized, and conformational change (protein folding) may occur. The fact that Myb-KAmut caused higher DNA binding capacity and transactivating potential than c-Myb indicates that acetylation of c-Myb at K471/480/485 per se may cause conformational change, thereby increasing the DNA binding activity and transcriptional activity. It is very suggestive that altered DNA binding activity and transactivating capacity is well correlated to the acetylation intensity by p300 in vitro. Namely, acetylation eciency was reduced only by 80% compared to wild type c-Myb by introducing the mutations in three lysines. In accordance with the reduction, DNA binding activity slightly but signi®-cantly increased and thus transactivating potential was slightly upregulated. More drastic change was observed between untreated c-Myb and p300-treated c-Myb. Under the condition that ecient acetylation was observed by the addition of p300 to wild type cMyb, approximately ®vefold increase in DNA binding capacity was obtained, and the transcriptional activity was prominently upregulated. These results strongly indicate that the acetylation of c-Myb by p300 enhances DNA binding capacity and transactivating potential.
Interestingly, the transactivation activity of MybKAmut in the presence of co-transfected p300 was higher than that of c-Myb with co-transfected p300. This indicates that elevated Myb-dependent transactivation by p300 is not only obtained through the acetylation of the lysines K471/480/485. One possibility is that p300 acetylates other lysines in vivo. Our data from in vivo acetylation assay using antiacetylated lysine antibody and in vitro acetylation assay using 14 C-acetyl coenzyme A indicate the existence of other acetylation sites for p300. It is possible that the acetylation sites of p300 other than Figure 6 The mutations at the acetylation site aect the c-Myb-induced transcription activity. Relative luciferase activity is indicated. pcDNA-c-Myb and pcDNA-Myb-KAmut were transfected into 293T cells (2610 5 ) with or without pCMV-p300. Transactivating activity of Myb-KAmut was signi®cantly higher than that of c-Myb in relation to mim-1 (a) and CD34 (b) promoters. When p300 was cotransfected, c-Myb or Myb-KAmut dependent activity was signi®cantly enhanced. Each activity was standardized with b-galactosidase activities (Tomita et al., 1998) lack the negative regulatory domain (NRD) including a portion of the`conserved domain', but still retains the leucine-zipper domain. The NRD negatively regulates both the transactivating and transforming capacities of c-Myb. The putative inhibitor(s) is thought to bind to c-Myb through the leucine zipper motif in the NRD and to repress the cMyb activity. It has been reported that the DNAbinding activity increased twofold by deleting the entire conserved domain of c-Myb (Tanaka et al., 1997) . These observations might be a re¯ection of the loss of these lysine residues (K471/480/485), and other potential acetylated lysines. The C-terminally truncated Myb protein has been shown to have much higher transactivating and transforming activity than wild type c-Myb (Tomita et al., 1998; Grasser et al., 1991) . These results suggest that the increased transactivation capability produced by the deletion of C-terminal domain of c-Myb may be the result not only of a loss of the acetylation sites at K471/480/485 but also of a loss of other acetylation sites and/or phosphorylation sites which are critical for the full activation. An Myb protein lacking all acetylation sites, which can be generated by the additional mutations to Myb-KAmut at other possible acetylation sites, may act per se as an`oncoprotein', and be as eective as the truncated Myb (such as v-Myb) in certain hematopoietic malignancies. c-Myb can also be acetylated by hGCN5 in vitro acetylation assay (Figure 4b,c) indicates that the acetylation ecacy of Myb-KAmut is lower than that of c-Myb. This raises the possibility that GCN5 is also a factor acetyltransferase for c-Myb. In the case of p53, other acetylation sites are regulated by dierent acetyltrasnferases in independent situations (Sakaguchi et al., 1998) . Further studies including in vivo acetylation assays are required in order to elucidate the signi®cance of GCN5 as a factor acetyltransferase (FAT) for c-Myb, and for dierences in substrate speci®city, if any, between p300 and GCN5. While the acetyltransferase activity of hGCN5 for histone is signi®cantly lower than that of p300 (Figure 4b ), the activity of hGCN5 for c-Myb is higher than that of p300 (Figure 4c) . Furthermore, the addition of the bromodomain to HAT domain apparently enhanced the acetylation ecacy of p300 for c-Myb. According to histone and p53, the HAT domain was reported to be sucient for their acetylation (Ogryzko et al., 1996; Gu and Roeder, 1997) , in contrast to the data of cMyb (Figure 4b,c) . Very recently, a structural analysis of the bromodomain was reported and the bromodomain was shown to interact speci®cally with acetylated lysing (Dhalluin et al., 1999) . Taken together with the fact that another histone acetyltransferases, such as CBP, P/CAF, and TAF230, have`bromodomains', it may be that this domain functions to recognize substrate speci®city.
In conclusion, we have presented some new insights on an important hematopoietic-speci®c transcription factor, c-Myb: (1) p300 is a factor acetyltransferase for c-Myb both in vitro and in vivo; (2) the acetylation sites of c-Myb are located in the C-terminal conserved region; (3) the acetylation modulates the c-Mybdependent DNA binding activity and transcriptional activity; and (4) the bromodomain of p300 is required in addition to the HAT domain for eective c-Myb acetylation. This report not only introduces a novel mechanism for how the transcriptional activity of cMyb is regulated, but also provides a clue for considering how c-Myb acts as an`oncoprotein'.
Materials and methods
Construction of expression vector and luciferase reporter vectors
The expression vectors pcDNA-c-myb and pcDNA-WTK-1, which express full-length (wild type) c-Myb and Myb(1-402), respectively, have been described previously (Tomita et al., 1998) . For the expression of C-terminal-truncated Myb proteins, adequate polymerase chain reaction (PCR) fragments containing termination codons at the 3' ends were inserted at the BamHI site of pcDNA-WTK-1.
A triple mutation at K471/480/485 into alanine was made by in vitro mutagenesis, and inserted in the pcDNA vector. pCMV-p300 was provided by A Fukamizu. pGEX-c-Myb, pGEX-WTK-1, pGEX-p300 mutants, and GST-GCN5, which expressed glutathion S-transferase (GST) fusion protein containing c-Myb, Myb(1-402), the HAT domain and/or bromodomain (Br) of the p300 (GST-BrHAT; 1053 ± 1810 aa, GST-Br; 1053 ± 1257 aa, GST-p300-HAT; 1195 ± 1810 aa) protein, and full length human GCN5, were made by PCR cloning. Because the autoacetylation bands of GSTp300-HAT were the same size as GST-c-Myb, GST-p300-HAT protein was cleaved by thrombine to obtain p300-HAT protein. The fragments of a triple mutant, with mutations at K471, K480, and K485 of c-Myb into alanines, was inserted into a pGEX vector to generate GST fused Myb mutant proteins (Myb-KAmut).
A CD34-Luc reporter was constructed with the PCR method by inserting the CD34 promoter sequence (7666 to +258) into a pGVE2 luciferase vector (Toyo Ink Mfg. Co., Ltd, Tokyo, Japan) (Melotti et al., 1994; Burn et al., 1992) . The mim-1-Luc reporter vector (provided by Dr SA Ness) containing mim-1 promoter sequence was described previously (Tomita et al., 1998; Ness et al., 1989) . Each construct was con®rmed by sequencing using ABI 310 autosequencer.
In vitro acetylation assays
For the analysis of in vitro acetylation of C-terminal truncated c-Myb protein, non-radioisotope-labeled recombinant Myb and p300 proteins were translated using a TNT coupled reticulocyte lysate system (Promega, Madison, WI, USA). After determining the translation ecacy by immunoblotting using anti-Myb antibody, the reaction mixtures of each protein, 10 mM of sodium butyrate, 1 mM DTT, and 100 pCi of [1-14 C]acetyl-coenzyme A (Amersham, Little Chalfont, UK) were incubated at 308C for 1 h and subjected to SDS ± PAGE. The autoradiography of the dried gels was performed by exposing to phosphor imaging plates (Fuji Photo Film, Kanagawa, Japan) for 4 ± 7 days.
To compare the acetylation level of histone (1 mg) (Boehringer Mannheim, Germany), c-Myb, and Myb-KAmut (250 ng each), each protein was mixed with GST-BrHAT, GST-p300-Br, p300-HAT, or GST-GCN5 (50 ng each) in 50 mM Tris-HCl with 10 mM of sodium butyrate, 1 mM DTT, and 50 pCi of [1-14 C]acetyl-coenzyme A at 378C for 80 min. Detection was performed as described above. The intensity of acetylation was measured by using NIH image computer graphic software (Nakahara et al., 1999) . Rabbit polyclonal antibody speci®c for acetylated lysine residue was raised against synthesized peptide SGRGK(Ac)GGKG, and sera from immunized rabbits were anity puri®ed using SHLKSKK(Ac)GQSTSRC. This antibody reacted with peptides, histone H4-(Ac)K8, Histone H4-(Ac)K12, Histone H4-(Ac)K16, Histone H3-(Ac)K14, p53-(Ac)K382 (STSRHKK(Ac)LMFKTEC), and p53-(Ac)K373 (SHLKSKK(Ac)GQSTSRC), but did not react with unacetylated peptides (CycLex Inc., Ina, Nagano, Japan).
Cell culture conditions, transient transfection assays and luciferase assays 293T cells, a human embryonic kidney cell line, were cultured in Dulbecco's Modi®ed Eagle Medium (GibcoBRL, Grand Island, NY, USA) containing 10% fetal bovine serum for transient transfection assay. Transfection was performed by calcium phosphate method and luciferase activity was standardized by b-galactosidase activity generated by cotransfected b-galactosidase expression vector (pSV-b-galactosidase control vector, Promega). The input doses of each expression vector were equalized with respective empty vectors.
Immunoprecipitation of c-Myb proteins and GST-fused c-Myb protein
The indicated expression vectors were co-transfected to 6610 5 of 293T cells by calcium phosphate method. Cells were lysed in lysis buer (100 mM NaCl, 20 mM Tris-HCl pH 8.0, 40 mM Na pyrophosphate, 5 mM EDTA, 0.5% Triton X, 0.25% NaDOC, 20 mg/ml aprotinin, 20 mg/ml leupeptin, 20 mg/ml pepstatin A, 1 mM DTT, 1 mM Na vanadate, and 1 mM PMSF). The extracts were used for immunoprecipiation by using c-Myb monoclonal antibody (Upstate Biotechnology, Lake Placid, NY, USA) and protein G sepharose (Pharmacia). Anti-Myb antibody (kindly provided by SA Ness) and anti-p300 antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) were used for immunoblot.
All the GST fusion proteins were expressed in E. coli and puri®ed by using glutathione sepharose 4B beads (Pharmacia Biotech, Uppsala, Sweden). All the GST-fused proteins were con®rmed by SDS ± PAGE followed by Coomassie blue staining and/or immunoblotting (data not shown).
Electrophoretic mobility shift assay (EMSA)
Gel shift experiments were performed as described (Guehmann et al., 1992) . The Myb consensus oligonucleotide (5'-TAACGGTT-3') (Santa Cruz Biotechnology) was used as a probe in this assay. Anti-GST antibody (Pharmacia) was used for supershift assay. In vitro acetylation of GST-fused Myb protein was performed as described above by using nonradiolabeled acetyl co-enzyme-A and GST-p300-BrHAT acetyltransferase.
